THERAPEUTIC OPPORTUNITY SCREENING

Powering the Age of Immune Medicine with Next-Gen Protein Simulation.

Our vision. Today, explore the research-prioritisation workspace in demo mode.

Find the right therapeutic application for your platform. Indica Bio is being developed to help teams prioritise therapeutic opportunities by unmet medical need, commercial potential, and the rationale for their delivery approach.

Explore our approach

Early-stage project · LMU Startup in 2 Days

Proposed screening framework
  1. 01Platform context
  2. 02Candidate applications
  3. 03Evidence across three criteria
  4. 04Shortlist for expert review

A platform can have many applications. Choosing where to focus is the hard part.

A platform technology can point toward many therapeutic uses. The decision is which applications warrant deeper investigation, given the platform's capabilities, constraints, and potential clinical and commercial relevance.

Indica Bio is being developed so that choice can be made explicit before a team commits to a longer scientific and commercial review.

The question was raised by Prof. Baldauf, Virology, LMU. The team is taking it up during LMU Startup in 2 Days.

Platform research image

INTENDED WORKFLOW

From platform context to a shortlist for expert review.

These four steps are the intended workflow. They describe how screening is meant to work. They do not describe a finished product.

  1. 01

    Define the platform.

    Capture capabilities, constraints, and intended use.

  2. 02

    Explore candidate applications.

    Identify possible therapeutic applications for evaluation.

  3. 03

    Compare the evidence.

    Consider the selected criteria while exposing assumptions and evidence gaps.

  4. 04

    Prioritise the next investigation.

    Develop a shortlist for deeper scientific and commercial review.

What the workspace is meant to help with

These are intentions, not measured outcomes. The workspace does not claim time savings, cost reductions, or lower inference latency.

  • Compare model options without committing the interface to one provider.
  • Structure evidence and assumptions in one workspace.
  • Prepare research questions for collaboration and expert review.
  • Reduce repetitive research coordination through planned workflows.

Three considerations, held open for expert review.

The example in the brief is prioritising therapeutic proteins. It asks where unmet medical need, commercial potential, and a delivery rationale could justify a closer look.

01

Unmet medical need

Whether an application addresses a condition that current care does not serve well. This is a qualitative question for later expert review, not a score.

02

Commercial potential

Whether an application could support a credible path toward development and adoption. No market size is claimed here.

03

Delivery rationale

For the protein example, where giving the protein directly could have a specific advantage over an mRNA- or DNA-based approach.

The platform technology, the dataset, how these criteria should be weighted, and what would count as success have not been defined yet.

Intended audiences

The project is being shaped for the groups below. They are intended audiences. Indica Bio does not yet have customers.

  1. 01

    Biotech platform teams

    Teams deciding which therapeutic uses of a platform deserve a deeper look.

  2. 02

    Translational research groups

    Groups connecting a technology with a clinical question.

  3. 03

    Technology-transfer teams

    Teams weighing how a research platform might move toward an application.

  4. 04

    Therapeutic business-development teams

    Teams comparing application paths before a larger commercial review.

Team

The people taking part in LMU Startup in 2 Days. The notes below describe what each person brings to this project.

  • Portrait to be added

    Lenn Borzym

    Customer insight. Runs an AI community platform for students.

  • Portrait to be added

    Himanshu Sachdeva

    Domain expertise. Founder of Thaevon Biosciences, working in synthetic biology and AI.

  • Portrait to be added

    Tianyi Cao

    Builder. Core AI agent systems, with a protein and lipid nanoparticle production and quality-control idea.

  • Portrait to be added

    Suriyaa Sundararuban

    Sales and business development. Medicine, serial entrepreneurship, and AI × oncology.

FAQ

A few limits, stated plainly.

Is Indica Bio available today?

A signed-in demonstration workspace is part of this website. It does not run live scientific analysis or protein simulation. Indica Bio is not commercially available, and it has not been scientifically validated as a product.

What would the screening produce?

The intended result is a shortlist of therapeutic applications for deeper scientific and commercial review. It would not be a validated therapeutic recommendation.

Does Indica Bio assume protein delivery is always preferable?

No. The relevant comparison depends on the protein, indication, and platform. No delivery modality is assumed to be universally preferable.

Is this a clinical decision tool?

No. It is intended for research and commercial assessment. It is not a clinical decision tool, and it does not give medical advice.

Working out where your platform fits?

We're speaking with researchers and biotech teams about how they identify and prioritise therapeutic applications.

We're preparing our discovery conversations. Contact details will be published here.